Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
Holding GH?
Track your performance easily
GH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.81 - $37.04
Previous Close$32.65
Volume2.17M
Average Volume (3M)2.13M
Market Cap
$4.03B
Enterprise Value$5.04B
Total Cash (Recent Filing)$310.70M
Total Debt (Recent Filing)$1.31B
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Feb 20, 2025EPS Estimate
-$0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.24
Shares Outstanding123,554,612
10 Day Avg. Volume2,581,825
30 Day Avg. Volume2,131,320
Standard Deviation0.17
R-Squared0.12
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-62.61
Price to Sales (P/S)5.48
Price to Cash Flow (P/CF)-18.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.27
Enterprise Value/Gross Profit14.95
Enterprise Value/Ebitda-8.84
Forecast
1Y Price Target
$43.33Price Target Upside32.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Guardant Health News
PremiumCompany Announcements
Guardant Health Boosts 2024 Revenue Outlook
PremiumCompany Announcements
Guardant Health Appoints Roberto Mignone to Board
Bulls Say, Bears Say
Bulls Say
FDA Approval And Market MomentumThe company's Shield test is accelerating after FDA approval and Medicare reimbursement, showing strong momentum and early volume ahead of expectations.
Market Share And Long-Term GrowthGuardant Health is on track to increase its share in the large colon cancer screening market with the adoption of Shield, contributing positively to long-term growth potential.
Revenue Growth And Market StrategyGuardant Health has raised its 2024 revenue guidance due to better than expected third-quarter results and increased expectations for biopharma revenue.
Bears Say
Financial PerformanceThe likelihood of performance degradation in EXAS pivotal readout.
Product EffectivenessAdvanced precancerous lesion sensitivity was relatively low at 31.2%.
Technology ReliabilityExperts doubt the accuracy of imaging-based approaches.
---
Ownership Overview
3.87% Insiders
29.90% Mutual Funds
42.14% Other Institutional Investors
7.29% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $15.81 and its highest was $37.04 in the past 12 months.
What is Guardant Health’s market cap?
Currently, no data Available
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Feb 20, 2025 which is in 88 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on Nov 06, 2024. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.73 by -$0.15.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -$0.78.
How many shares outstanding does Guardant Health have?
Guardant Health has 123,554,610 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.73. Following the earnings report the stock price went up 13.049%.
Which hedge fund is a major shareholder of Guardant Health?
Among the largest hedge funds holding Guardant Health’s share is ARK Investment Management LLC. It holds Guardant Health’s shares valued at 35M.
---
Guardant Health Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.33 (32.71% Upside)
$43.33 (32.71% Upside)
Blogger Sentiment
Bullish
GH Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $536.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.55%
12-Months-Change
Fundamentals
Return on Equity
-609.28%
Trailing 12-Months
Asset Growth
-14.38%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
---
GH Company Deck
---
GH Earnings Call
Q3 2024
0:00 / 0:00
---
GH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
---
GH Stock 12 Month Forecast
Average Price Target
$43.33
▲(32.71% Upside)
Technical Analysis
Best Analysts Covering GH
1 Year
1 Year Success Rate
9/12 ratings generated profit
1 Year Average Return
+25.56%
assigned a buy rating 18 days ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +25.56% per trade.
---